Logotype for Dr. Reddy’s Laboratories Limited

Dr. Reddy’s Laboratories (DRREDDY) investor relations material

Dr. Reddy’s Laboratories Q2 25/26 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Dr. Reddy’s Laboratories Limited
Q2 25/26 earnings summary24 Oct, 2025

Executive summary

  • Q2FY26 revenue grew 9.8% year-over-year and 3% sequentially, reaching ₹88.1 billion, with broad-based growth across markets except North America, which faced price erosion and lower Lenalidomide sales.

  • Profit after tax attributable to equity holders was ₹14.4 billion, up 14% year-over-year and 1% sequentially.

  • Strategic acquisitions, including the NRT and Stugeron portfolios, and new product launches in India, APAC, and EMEA supported growth.

  • Continued focus on innovation, biosimilars, and consumer healthcare, with key regulatory progress in multiple regions.

  • ESG achievements included maintaining MSCI ESG rating 'A', improved Sustainalytics risk rating, and LEED Platinum certification for Srikakulam facility.

Financial highlights

  • Consolidated revenue for Q2FY26 was ₹88.1 billion (₹8,805 crore), up 9.8% year-over-year and 3% sequentially.

  • EBITDA was ₹23.5 billion (₹2,351 crore), with a margin of 26.7%, up 3% year-over-year and sequentially.

  • Gross margin was 54.7%, down 492 bps year-over-year, mainly due to lower Lenalidomide sales and price erosion in North America.

  • Diluted EPS for Q2FY26 was ₹17.25.

  • Net cash surplus as of September 30, 2025, was ₹27.5 billion (₹2,751 crore).

Outlook and guidance

  • Management is focused on strengthening core businesses, advancing pipeline assets, and driving operational efficiencies.

  • Confident in maintaining double-digit growth in ex-US markets over the next 1-2 years, supported by new launches and innovation.

  • Commitment to restoring EBITDA margins to 25%+ in the next two years, with growth levers including semaglutide, abatacept, and business development.

  • Emphasis on augmenting organic growth with M&A and in-licensing, and maintaining quality, compliance, and sustainability.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Dr. Reddy’s Laboratories earnings date

Logotype for Dr. Reddy’s Laboratories Limited
Q3 25/2622 Jan, 2026
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Dr. Reddy’s Laboratories earnings date

Logotype for Dr. Reddy’s Laboratories Limited
Q3 25/2622 Jan, 2026

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Dr. Reddy’s Laboratories, an integrated pharmaceutical company worldwide, discovers, develops, manufactures and markets innovative branded generic pharmaceuticals and formulations in specialty areas primarily neurology and psychiatry. The company also markets and distributes products, including pharmaceutical intermediates and active pharmaceutical ingredients (APIs); animal health-related products; nutraceuticals/food supplements; and chemicals. The company offers a range of products comprising of tablets, capsules, fine granules, liquids and injectable pharmaceuticals, transdermal patches, ointments, creams, sprays and others. It markets its products through wholesalers and distributors to pharmacies, pharmacists and hospitals; chain drug stores; mass market retailers; e-commerce websites; government institutions; missionary organizations; etc.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage